Overview

Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy

Status:
Terminated
Trial end date:
2020-09-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of the Asthma improvement of Flutiform K-haler after 12 weeks of treatment in patients with moderate to severe uncontrolled* asthma following mid-dose ICS/LABA DPI therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Mundipharma Korea Ltd